A new treatment approach for Multiple Sclerosis using synthetic biology.
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
['FUNDING_SBIR_2'] · RISE THERAPEUTICS, LLC · NIH-11049506
This study is testing a new treatment for Multiple Sclerosis that uses the body's natural gut bacteria to help balance the immune system, with the hope of improving health and quality of life for people living with MS.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RISE THERAPEUTICS, LLC (nih funded) |
| Locations | 1 site (Rockville, UNITED STATES) |
| Trial ID | NIH-11049506 on ClinicalTrials.gov |
What this research studies
This research aims to develop a novel therapeutic that utilizes synthetic biology and immunological principles to treat Multiple Sclerosis (MS). The approach focuses on leveraging the body's natural microbiome to restore immune balance, which is crucial for managing MS symptoms and preventing complications. By targeting the gut-brain axis, the therapy seeks to enhance the production of regulatory T cells and anti-inflammatory cytokines, potentially improving the overall health and quality of life for patients with MS. The treatment will be administered orally, aiming for localized effects in the gut to influence systemic immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Multiple Sclerosis who are experiencing symptoms related to the disease.
Not a fit: Patients with other neurological disorders or those who do not have a diagnosis of Multiple Sclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option that significantly improves the management of Multiple Sclerosis and enhances patients' quality of life.
How similar studies have performed: Other research has shown promising results in using microbiome-based therapies for autoimmune diseases, indicating potential success for this novel approach.
Where this research is happening
Rockville, UNITED STATES
- RISE THERAPEUTICS, LLC — Rockville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FURLAN FREGUIA, CHRISTIAN — RISE THERAPEUTICS, LLC
- Study coordinator: FURLAN FREGUIA, CHRISTIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases